NewLimit
NewLimit is creating epigenetic reprogramming medications to cure diseases with significant unmet medical needs.
Biotechnology
📍 South San Francisco, CA
Founded 2021
Current Valuation
$1.6B
as of 2025-Q4
UNICORN
NewLimit is creating epigenetic reprogramming medications to cure diseases with significant unmet medical needs.
Company Profile
HQ
South San Francisco, CA
Last Round
Early Stage VC — $45M (Oct 2025)
Fundraising Status
Early Stage VC · $45M · 8 mo ago
privateTotal raised $247M
Latest Funding Round
| Round | Amount | Date | Lead Investor | Post-Money |
|---|
| Early Stage VC | $45M | Oct 2025 | — | $1.6B |
Clinical TrialsHealth CareBiotechnology
Private-company numbers are not real-time. Reflects publicly disclosed valuations from press releases, news reports, and tender offers as of 2025-Q4. Refreshed quarterly.